Aviva plc (OTCMKTS:AVVIY – Get Free Report) was the target of a large decrease in short interest in the month of January. As of January 15th, there was short interest totalling 14,700 shares, a decrease of 75.8% from the December 31st total of 60,800 shares. Based on an average daily trading volume, of 77,800 shares, the short-interest ratio is presently 0.2 days.
Aviva Price Performance
OTCMKTS:AVVIY traded up $0.04 during trading hours on Thursday, hitting $12.83. 11,176 shares of the company traded hands, compared to its average volume of 31,200. Aviva has a twelve month low of $10.50 and a twelve month high of $13.58. The firm has a 50-day moving average of $12.17 and a 200 day moving average of $12.56.
Wall Street Analyst Weigh In
AVVIY has been the subject of several recent analyst reports. Keefe, Bruyette & Woods raised shares of Aviva from a “hold” rating to a “moderate buy” rating in a report on Wednesday, November 27th. BNP Paribas raised shares of Aviva from a “strong sell” rating to a “hold” rating in a report on Thursday, December 5th. Royal Bank of Canada upgraded shares of Aviva to a “moderate buy” rating in a research note on Thursday, October 3rd. Finally, Hsbc Global Res upgraded shares of Aviva from a “hold” rating to a “strong-buy” rating in a research note on Friday, November 15th. One investment analyst has rated the stock with a hold rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of “Buy”.
About Aviva
Aviva plc provides various insurance, retirement, investment, and savings products in the United Kingdom, Ireland, Canada, and internationally. The company offers life insurance, long-term health and accident insurance, savings, pension, and annuity products, as well as pension fund business and lifetime mortgage products.
Read More
- Five stocks we like better than Aviva
- What is the Shanghai Stock Exchange Composite Index?
- How Value Investors Find Undervalued Stocks and Build Wealth
- When to Sell a Stock for Profit or Loss
- Is Tonix Pharmaceuticals the Next Biotech Breakout?
- Conference Calls and Individual Investors
- DeepSeek Dip: Is the Nuclear Energy Sell-Off a Buying Opportunity
Receive News & Ratings for Aviva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aviva and related companies with MarketBeat.com's FREE daily email newsletter.